The prisoner's face lit up when his wife visited and told him that the man responsible for his detention was himself behind ...
Pfizer Inc. today announced positive results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, ...
Over 70 percent of patients in the first-line subgroup responded to amivantamab plus chemotherapy with most responses lasting beyond 16 monthsNotable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results